RedHill Biopharma Ltd. SEC filings RDHL
RedHill Biopharma Ltd. has 1,000 filings in SEC EDGAR's recent list, going back to Mar 6, 2013. Its latest annual report, Form 20-F, was filed on Apr 27, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Nov 2, 2026.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Jul 13, 2026 | — |
| EFFECT | Filing | May 5, 2026 | — |
| EFFECT | Filing | Jan 27, 2026 | — |
| CORRESP | Letter to the SEC | Jan 26, 2026 | — |
| UPLOAD | Letter from the SEC | Jan 6, 2026 | — |
| EFFECT | Filing | Sep 9, 2025 | — |
| EFFECT | Filing | Sep 9, 2025 | — |
| EFFECT | Filing | Jul 2, 2025 | — |
| CORRESP | Letter to the SEC | Jun 30, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 30, 2025 | — |
| EFFECT | Filing | Aug 19, 2024 | — |
| CORRESP | Letter to the SEC | Aug 15, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 15, 2024 | — |
| EFFECT | Filing | Apr 22, 2024 | — |
| EFFECT | Filing | Feb 15, 2024 | — |
| CORRESP | Letter to the SEC | Feb 15, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 14, 2024 | — |
| D | Filing | Feb 5, 2024 | — |
| EFFECT | Filing | Oct 26, 2023 | — |
| CORRESP | Letter to the SEC | Oct 26, 2023 | — |
| D | Filing | Oct 12, 2023 | — |
| EFFECT | Filing | Aug 11, 2023 | — |
| CORRESP | Letter to the SEC | Aug 9, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 9, 2023 | — |
| D | Filing | Aug 7, 2023 | — |
| D | Filing | Nov 22, 2021 | — |
| EFFECT | Filing | Aug 9, 2021 | — |
| CORRESP | Letter to the SEC | Aug 5, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 4, 2021 | — |
| CT ORDER | Filing | Jun 24, 2021 | — |
| SC TO-I/A | Filing | May 26, 2021 | — |
| SC TO-I | Filing | Apr 26, 2021 | — |
| EFFECT | Filing | Apr 8, 2021 | — |
| CORRESP | Letter to the SEC | Apr 6, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 5, 2021 | — |
| CT ORDER | Filing | Mar 30, 2020 | — |
| D | Filing | Nov 6, 2019 | — |
| EFFECT | Filing | Aug 8, 2019 | — |
| CORRESP | Letter to the SEC | Aug 6, 2019 | — |
| UPLOAD | Letter from the SEC | Jul 31, 2019 | — |
| CT ORDER | Filing | May 9, 2019 | — |
| CT ORDER | Filing | Mar 4, 2019 | — |
| CT ORDER | Filing | Nov 16, 2018 | — |
| EFFECT | Filing | Jul 31, 2018 | — |
| UPLOAD | Letter from the SEC | Jul 31, 2018 | — |
| CORRESP | Letter to the SEC | Jul 31, 2018 | — |
| CT ORDER | Filing | Apr 25, 2018 | — |
| CT ORDER | Filing | May 30, 2017 | — |
| CT ORDER | Filing | Mar 24, 2017 | — |
| CT ORDER | Filing | Feb 28, 2017 | — |
| UPLOAD | Letter from the SEC | Sep 13, 2016 | — |
| CORRESP | Letter to the SEC | Aug 31, 2016 | — |
| UPLOAD | Letter from the SEC | Aug 16, 2016 | — |
| CT ORDER | Filing | Jun 27, 2016 | — |
| EFFECT | Filing | Mar 11, 2016 | — |
| CORRESP | Letter to the SEC | Mar 9, 2016 | — |
| UPLOAD | Letter from the SEC | Mar 8, 2016 | — |
| CT ORDER | Filing | Oct 20, 2015 | — |
| CT ORDER | Filing | Oct 20, 2015 | — |
| CT ORDER | Filing | Jul 14, 2014 | — |
| EFFECT | Filing | Feb 4, 2014 | — |
| D | Filing | Jan 15, 2014 | — |
Showing 62 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RDHL (Nasdaq)
- Incorporated in
- Israel
- Headquarters
- Tel Aviv, Israel
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1553846
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.